NCT04799275 2026-04-14
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Suspended
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Children's Cancer Group, China
University of Birmingham
St. Jude Children's Research Hospital
Karyopharm Therapeutics Inc
Incyte Corporation